Global Drugs for Vulvovaginal Candidiasis Market Research Report 2023

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2023

Table of Contents
1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Product Overview and Scope of Drugs for Vulvovaginal Candidiasis
1.2 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2023-2029)
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Value by Application: (2023-2029)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
1.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2018-2029
1.4.2 Global Drugs for Vulvovaginal Candidiasis Sales 2018-2029
1.4.3 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Drugs for Vulvovaginal Candidiasis Market Competition by Manufacturers
2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2018-2023)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2018-2023)
2.4 Global Drugs for Vulvovaginal Candidiasis Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
2.7 Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
2.7.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
2.7.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario by Region
3.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Drugs for Vulvovaginal Candidiasis Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2018-2029
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2018-2023
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2024-2029
3.3 Global Drugs for Vulvovaginal Candidiasis Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2018-2029
3.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2018-2023
3.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2024-2029
3.4 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.4.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2029)
3.4.3 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.5.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2029)
3.5.3 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2029)
3.6.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.7.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2029)
3.7.3 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2029)
3.8.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2018-2029)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2018-2023)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2024-2029)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2018-2029)
4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2018-2029)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2018-2023)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2024-2029)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2018-2029)
4.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2018-2029)
5 Segment by Application
5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2018-2029)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2018-2023)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2024-2029)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2018-2029)
5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2018-2029)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2018-2023)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2024-2029)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2018-2029)
5.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Perrigo
6.2.1 Perrigo Corporation Information
6.2.2 Perrigo Description and Business Overview
6.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
6.2.5 Perrigo Recent Developments/Updates
6.3 J & J
6.3.1 J & J Corporation Information
6.3.2 J & J Description and Business Overview
6.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
6.3.5 J & J Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Effik
6.6.1 Effik Corporation Information
6.6.2 Effik Description and Business Overview
6.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
6.6.5 Effik Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 Cisen Pharmaceutical
6.9.1 Cisen Pharmaceutical Corporation Information
6.9.2 Cisen Pharmaceutical Description and Business Overview
6.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
6.9.5 Cisen Pharmaceutical Recent Developments/Updates
6.10 Kingyork Group
6.10.1 Kingyork Group Corporation Information
6.10.2 Kingyork Group Description and Business Overview
6.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
6.10.5 Kingyork Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
7.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process
7.4 Drugs for Vulvovaginal Candidiasis Sales and Marketing
7.4.1 Drugs for Vulvovaginal Candidiasis Sales Channels
7.4.2 Drugs for Vulvovaginal Candidiasis Distributors
7.5 Drugs for Vulvovaginal Candidiasis Customers
8 Drugs for Vulvovaginal Candidiasis Market Dynamics
8.1 Drugs for Vulvovaginal Candidiasis Industry Trends
8.2 Drugs for Vulvovaginal Candidiasis Market Drivers
8.3 Drugs for Vulvovaginal Candidiasis Market Challenges
8.4 Drugs for Vulvovaginal Candidiasis Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation by Manufacturers in 2022
Table 4. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Drugs for Vulvovaginal Candidiasis, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
Table 12. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2018-2023) & (K Units)
Table 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2018-2023)
Table 19. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2024-2029) & (K Units)
Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2024-2029)
Table 21. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2018-2023)
Table 23. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2024-2029)
Table 25. North America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2023) & (K Units)
Table 27. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2024-2029) & (K Units)
Table 28. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2023) & (K Units)
Table 32. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2024-2029) & (K Units)
Table 33. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2018-2023)
Table 51. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2024-2029)
Table 52. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2018-2023)
Table 53. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2024-2029)
Table 54. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2018-2023)
Table 57. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2024-2029)
Table 58. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2018-2023)
Table 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2024-2029)
Table 60. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2018-2023)
Table 61. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2024-2029)
Table 62. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2018-2023)
Table 63. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2024-2029)
Table 64. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2018-2023)
Table 67. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2024-2029)
Table 68. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2018-2023)
Table 69. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2024-2029)
Table 70. Bayer Corporation Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 74. Bayer Recent Developments/Updates
Table 75. Perrigo Corporation Information
Table 76. Perrigo Description and Business Overview
Table 77. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 79. Perrigo Recent Developments/Updates
Table 80. J & J Corporation Information
Table 81. J & J Description and Business Overview
Table 82. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. J & J Drugs for Vulvovaginal Candidiasis Product
Table 84. J & J Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Effik Corporation Information
Table 96. Effik Description and Business Overview
Table 97. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Effik Drugs for Vulvovaginal Candidiasis Product
Table 99. Effik Recent Developments/Updates
Table 100. Teva Corporation Information
Table 101. Teva Description and Business Overview
Table 102. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Teva Drugs for Vulvovaginal Candidiasis Product
Table 104. Teva Recent Developments/Updates
Table 105. Sanofi Corporation Information
Table 106. Sanofi Description and Business Overview
Table 107. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 109. Sanofi Recent Developments/Updates
Table 110. Cisen Pharmaceutical Corporation Information
Table 111. Cisen Pharmaceutical Description and Business Overview
Table 112. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 114. Cisen Pharmaceutical Recent Developments/Updates
Table 115. Kingyork Group Corporation Information
Table 116. Kingyork Group Description and Business Overview
Table 117. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 119. Kingyork Group Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Drugs for Vulvovaginal Candidiasis Distributors List
Table 123. Drugs for Vulvovaginal Candidiasis Customers List
Table 124. Drugs for Vulvovaginal Candidiasis Market Trends
Table 125. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 126. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 127. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Drugs for Vulvovaginal Candidiasis
Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Share by Type in 2022 & 2029
Figure 4. Cream Product Picture
Figure 5. Pessary Product Picture
Figure 6. Other Product Picture
Figure 7. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Drugs for Vulvovaginal Candidiasis Market Share by Application in 2022 & 2029
Figure 9. Hospital & Clinic
Figure 10. Pharmacy
Figure 11. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Drugs for Vulvovaginal Candidiasis Market Size (2018-2029) & (US$ Million)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales (2018-2029) & (K Units)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) & (2018-2029)
Figure 15. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 16. Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers in 2022
Figure 17. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players: Market Share by Revenue in 2022
Figure 19. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2018-2029)
Figure 22. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2018-2029)
Figure 23. U.S. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2018-2029)
Figure 26. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2018-2029)
Figure 27. Germany Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2018-2029)
Figure 34. China Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Philippines Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2018-2029)
Figure 45. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. U.A.E Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type (2018-2029)
Figure 55. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Type (2018-2029)
Figure 56. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Application (2018-2029)
Figure 58. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Application (2018-2029)
Figure 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2018-2029)
Figure 60. Drugs for Vulvovaginal Candidiasis Value Chain
Figure 61. Drugs for Vulvovaginal Candidiasis Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119

According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......

Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132

According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......

Global Contraceptives Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141

According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......

Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108

According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......

Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99

Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......

Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139

Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122

Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......

Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108

Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......

Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123

Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs